Back to Search Results
Travis O'Brien Travis O'Brien
Professor of Pharmacology and Physiology

Office Phone: (202) 994-3373
Email: Email
Department: Pharmacology and Physiology


  • B.S., Bowling Green State University, 1994
  • PhD, University of Cincinnati, 2000


I have been at The George Washington University, School of Medicine, and Health Sciences since 2000.  I am interested in the development of predictive pharmacogenomic/toxicogenomic biomarkers.  I have particular interest in improving biomarker discovery in underrepresented minority populations with cardiovascular disease.  As a medical educator I have spent the past 23 years teaching pharmacology, toxicology and pharmacogenomics to MD, PA, PharmD, PhD, MS, and undergraduate students. I also have an interest in scholarly activities examining the best practices for pharmacogenomics education in the health care professions. 



My laboratory focused on pharmacogenetic determinants of drug response.  Current research is focused on cardiovascular pharmacogenomics in African-Americans. 


Course Director or Co-Director for:
PHAR 6116, PHAR 6205, PHAR 6206, PHAR 6207, PHAR 6208, IDIS 207


Hernandez W, Gamazon ER, Aquino-Michaels K, Smithberger E, O'Brien TJ, Harralson AF, Tuck M, Barbour A, Cavallari LH, Perera MA. (2017) Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. (2017) J Thromb Haemost. Apr;15(4):735-743. doi: 10.1111/jth.13639. Epub 2017 Mar 25.

Hernandez, W, Gamazon,E,R,m Smithberger,E, Konkashbaevm A, O’Brien, T.J., Harralson, A.F., Tuck, M., Kittles, R.A., Cavallari, L.H., Perera, M.A. (2016) Novel genetic predictors of venous thromboembolism risk in African Americans, Blood Apr 14;127(15):1923-9. doi: 10.1182/blood-2015-09-668525. Epub 2016 Feb 17

O’Brien, T.J., Susan LeLacheur, Caitlin Ward, Shawneequa Callier, Arthur F. Harralson, (2016) Impact of personal CYP2D6 testing on physician assistant student attitudes towards pharmacogenetics, Pharmacogenomics Mar;17(4):341-52. doi: 10.2217/pgs.15.182. Epub 2016 Feb 24

Whitt, K., Macri, C., O'Brien, T., Wright, S. (2015) Improving Nurse Practitioners' Competence with Genetics: Effectiveness of an Online Course Journal of the American Academy of Nurse Practitioners Jun 25. doi: 10.1002/2327-6924.12282.

Orkunoglu-Suer, F., Harralson, A.F., Frankfurter, D, Gindoff, P., O’Brien, T.J. (2015) Targeted Single Molecule Sequencing Methodology for Ovarian Hyperstimulation Syndrome BMC Genomics 16:264.

O’Brien, T.J., Harralson, A.H., Tran, T, Gindoff, I.M., Orkunoglu-Suer, E.F, Frankfurter, D., Gindoff, P. (2015) Kinase Insert Domain Receptor/Vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome Reprod Biol Endocrinol Apr 3;16:264. doi: 10.1186/s12864-015-1451-2.

Callier, S, McCaffrey, T, Toma, I, Harralson, A.F., O'Brien, T.J., Engaging the Next Generation of Health Care Professionals in Genomics: Planning for the Future Personalized Medicine11(1), 89-98

Hernandez, W., Gamazon, E.R., Perry, K., Aquino-Michaels, K., Patel, S., O’Brien. T.J., Harralson, A.H., Kittles, R.A., Barbour, A., Tuck, M., Nicolae, D., Cavallari, L.H., Perera, M.A. (2013) Ethnicity-Specific Pharmacogenetics: The Case of Warfarin in African Americans Pharmacogenomics J. Jun;14(3):223-8. doi: 10.1038/tpj.2013.34. Epub 2013 Sep 10.

O’Brien, T.J., Marshall, M.M., Harralson, A.H., Clark, A.M., Gindoff, I.M., Simmens, S.J., Frankfurter, D and Gindoff, P (2013) The luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism is associated with ovarian hyperstimulation syndrome Reprod Biol Endocrinol.11(1), 71

O'Brien. T.J, Kidd, R.S., Richard, C.A.H, Ha, N., Witcher, P., Tran, L.V., Barbour, A., Tuck, M., McIntosh, S.D., Douglas, J.N., Harralson, A.F., (2013) First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele Clin Chim Acta. 2013 424C:73-75.

Green, J.S., O’Brien, T.J., Chiappinelli, V.A. and Harralson, A.H., (2010) Pharmacogenomics Instruction in United States and Canada Medical Schools: Implications for Personalized Medicine. Pharmacogenomics 11(9):1331-40.

Chun, G., Bae, D., O’Brien, T.J., Patierno, S.R. and Ceryak, S. (2010) Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass. Carcinogenesis 31(5):785-93.

O’Brien, T.J., Goodsaid, F., Plack. M, Harralson, A., Harrouk, W., Hales, T.G., Mandel, H.G., Perry, D., Kennedy, K. Sarvazyan, N. and Chiappinelli, V.A. (2009) Development of an Undergraduate Pharmacogenomics Curriculum Pharmacogenomics 10(12): 1979-1986.

O'Brien, T.J., Witcher, P., Brooks, B and Patierno, S.R. (2009) Cr(VI) Mutagenesis requires polymerase zeta-dependent translesion synthesis. Mutat. Res. 663 (1-2), 77-83.

Bae D., Camilli T.C., Chun G., Lal M., Wright K., O'Brien T.J., Patierno S.R. and Ceryak, S. (2009) Bypass of hexavalent chromium-induced growth arrest by a protein tyrosine phosphatase inhibitor: Enhanced survival and mutagenesis. Mutat. Res. 660(1-2):40-46

Brooks, B., O’Brien, T.J., Ceryak, S., DeFabo, E., Wise, S, Wise, J, Wise, J and Patierno, S.R. (2008) Excision Repair is required for genotoxin-induced mutagenesis in mammalian cells Carcinogenesis, 29(5):1064-9

O’Brien, T.J., Jiang, G.H., Chun, G, Mandel, H.G., Westphal, C.S., Kahen, K., Montaser, A., States, J.C., and Patierno, S.R. (2006) Incision of trivalent chromium [Cr(III)]-induced DNA damage by Bacillus caldotenax UvrABC endonuclease. Mutat. Res. 610(1-2):85-92.

Vilcheck, S.K., Ceryak. S., O’Brien, T.J. and Patierno, S.R. (2006) FANCD2 Monoubiquitination and Activation by Hexavalent Chromium [Cr(VI)] Exposure: Activation is not Required for Repair of Cr(VI)-induced DSBs. Mutat. Res. 610(1-2):21-30.

O’Brien, T.J., Mandel, H.G., Sugden, K.D., Komarov, A.M. Patierno, S.R. (2005) Hypoxia impedes the formation of chromium DNA-adducts in a cell-free system. Biochem Pharmacol 70(12), 1814-22

Industry Relationships and Collaborations

This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.

  • None